Shattuck Labs
STTK
5.66
-0.21
-3.50%
Shattuck Labs
US · STTK
#3662 by market cap
Listed 2020
5.66
-0.21
-3.50%
Live - 5344 symbols - heartbeat 215s ago
· 2026-10-08 09:11
Pre-market
5.65
-0.09%
After-hours
5.66
0.00%
Overnight
5.57
-1.50%
- Market cap
- 567.55M
- P/E (TTM)i
- -12.85
- P/Bi
- 2.69
- EPSi
- -0.70
- Div yieldi
- 0.00%
- 52W posi
- 60%
Reader sentiment
Are you bullish or bearish on STTK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 31.95, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -82.52% YoY
Margins
- Operating margin
- -5,150.80%
- Net margin
- -4,880.90%
Key ratios & quality
- Altman Z-Scorei
- 31.95
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.44M | 9.89M | 9.93M | 30.02M | 652.00K | 1.66M | 5.72M | 1.00M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.78M | 5.74M | 9.38M | 18.72M | 21.08M | 19.30M | 19.08M | 17.24M |
| Research & development | 24.81M | 29.22M | 37.48M | 56.56M | 82.90M | 74.31M | 67.21M | 35.27M |
| Operating profit | -6.15M | -25.07M | -36.93M | -45.27M | -103.33M | -91.96M | -80.57M | -51.51M |
| Pretax profit | -7.39M | -23.98M | -36.60M | -44.97M | -101.95M | -87.30M | -75.41M | -48.81M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -7.39M | -23.98M | -36.60M | -44.97M | -101.95M | -87.30M | -75.41M | -48.81M |
| Basic EPS | 0 | -1 | -2 | -1 | -2 | -2 | -1 | -1 |
| Diluted EPS | -0.49 | -1.26 | -2.36 | -1.07 | -2.41 | -2.05 | -1.49 | -0.70 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.00M | 0 | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.47M | 4.35M | 4.10M | 4.32M | 4.60M | 4.46M |
| Research & development | 9.92M | 8.68M | 7.62M | 9.06M | 10.95M | 11.70M |
| Operating profit | -14.39M | -13.03M | -10.72M | -13.37M | -15.55M | -16.16M |
| Pretax profit | -13.70M | -12.46M | -10.06M | -12.59M | -14.77M | -15.15M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -13.70M | -12.46M | -10.06M | -12.59M | -14.77M | -15.15M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.27 | -0.24 | -0.14 | -0.12 | -0.13 | -0.12 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 65.63M | 42.44M | 345.64M | 288.27M | 184.58M | 143.22M | 79.22M | 82.48M |
| Cash & ST investments | 60.38M | 39.09M | 335.45M | 268.80M | 161.28M | 130.63M | 72.99M | 78.07M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 68.16M | 44.97M | 348.99M | 298.59M | 205.32M | 159.56M | 91.05M | 91.03M |
| Total current liabilities | 20.85M | 19.98M | 16.83M | 24.59M | 24.97M | 11.45M | 8.92M | 7.05M |
| Short-term debt | -- | -- | -- | -- | 701.00K | 796.00K | 900.00K | 837.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 79,242,000.00 | 79,517,000.00 | 39,127,000.00 | 26,799,000.00 | 29,167,000.00 | 14,859,000.00 | 11,423,000.00 | 8,636,000.00 |
| Total equity | -11.08M | -34.55M | 309.86M | 271.79M | 176.16M | 144.71M | 79.63M | 82.39M |
| Retained earnings | -11.51M | -35.49M | -72.09M | -117.07M | -219.01M | -306.31M | -381.72M | -430.53M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 66.40M | 54.68M | 90.72M | 82.48M | 93.75M | 213.27M |
| Cash & ST investments | 60.90M | 50.47M | 86.13M | 78.07M | 90.42M | 208.30M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 77.17M | 64.37M | 100.33M | 91.03M | 102.12M | 220.67M |
| Total current liabilities | 7.32M | 5.34M | 5.34M | 7.05M | 4.25M | 7.73M |
| Short-term debt | 927.00K | 956.00K | 873.00K | 837.00K | 852.00K | 874.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 9,581,000.00 | 7,352,000.00 | 7,093,000.00 | 8,636,000.00 | 6,286,000.00 | 9,531,000.00 |
| Total equity | 67.59M | 57.02M | 93.24M | 82.39M | 95.84M | 211.14M |
| Retained earnings | -395.42M | -407.88M | -417.94M | -430.53M | -445.30M | -460.45M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -6.90M | -20.98M | -33.66M | -57.12M | -94.50M | -81.23M | -60.52M | -39.88M |
| Depreciation & amortization | 255.00K | 537.00K | 618.00K | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| Free cash flow | -8.08M | -21.45M | -34.39M | -65.04M | -106.11M | -81.64M | -60.57M | -39.95M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 232.30M | -- | 0 | 48.17M | -17.00K | 44.48M |
| Ending cash balance | 31.64M | 7.01M | 157.90M | 92.27M | 47.38M | 125.63M | 57.39M | 54.19M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -12.03M | -10.43M | -8.93M | -8.49M | -13.42M | -10.19M |
| Depreciation & amortization | 936.00K | 929.00K | 917.00K | 906.00K | 891.00K | 851.00K |
| Free cash flow | -12.03M | -10.43M | -9.00M | -8.49M | -13.42M | -10.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 44.48M | -5.00K | 20.56M | 80.43M |
| Ending cash balance | 60.90M | 50.47M | 42.55M | 54.19M | 90.42M | 63.30M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -26.59 | -15.46 | -45.52 | -54.41 | -67.23 | -60.25 |
| ROA %i | -10.84 | -42.40 | -18.58 | -13.89 | -40.46 | -47.85 | -60.18 | -53.61 |
| ROIC %i | -- | -- | -26.99 | -15.68 | -45.38 | -55.73 | -69.49 | -61.38 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -41.84 | -48.58 |
| EBIT margin %i | -21.20 | -242.56 | -371.76 | -150.81 | -15,848.01 | -5,549.61 | -1,408.27 | -5,150.80 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.15 | 2.12 | 20.53 | 11.72 | 7.39 | 12.51 | 8.88 | 11.70 |
| Quick ratioi | 2.90 | 1.96 | 19.93 | 10.93 | 6.46 | 11.41 | 8.19 | 11.07 |
| Debt / assetsi | -- | -- | -- | 0.00 | 2.39 | 2.63 | 3.74 | 2.66 |
| LT debt / equityi | -- | -- | -- | -- | 2.39 | 2.35 | 3.15 | 1.92 |
| Interest coveragei | -1.81 | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 10.18 | -59.60 | -44.95 | -42.45 | 15.32 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -71.90 | -73.39 | -57.84 | -60.25 | -61.04 | -39.21 |
| ROA %i | -63.18 | -63.75 | -51.77 | -53.61 | -55.64 | -36.88 |
| ROIC %i | -69.36 | -70.53 | -56.00 | -61.38 | -62.14 | -40.68 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,626.40 | -2,168.23 | -5,777.80 | -5,150.80 | -5,266.40 | -5,578.60 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.08 | 10.25 | 17.00 | 11.70 | 22.06 | 27.59 |
| Quick ratioi | 8.33 | 9.46 | 16.14 | 11.07 | 21.28 | 26.94 |
| Debt / assetsi | 4.14 | 4.62 | 2.62 | 2.66 | 2.83 | 1.21 |
| LT debt / equityi | 3.35 | 3.54 | 1.88 | 1.92 | 2.13 | 0.85 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Drug discovery and development100.00%
Region
United States100.00%
Quote time 2026-10-08 09:11:28 · For reference only, not investment advice and not tailored to your situation.